The intent of this study was to (1) investigate the prevalence of oncotype DX RS testing in women diagnosed with HR+/HER2– breast cancer and its association with mortality across age groups and nodal status, and (2) examine whether testing was associated with adjuvant chemotherapy use across both age and nodal status. Here, ERBB2 is linked to breast carcinoma.